Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Investment Securities (2016 - 2025)

Voyager Therapeutics' Gains from Investment Securities history spans 10 years, with the latest figure at $926636.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 582.62% year-over-year to $926636.0; the TTM value through Sep 2025 reached $926636.0, up 116.54%, while the annual FY2025 figure was -$141000.0, 101.6% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $926636.0 at Voyager Therapeutics, down from $1.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.8 million in Q1 2022 and bottomed at -$2.8 million in Q4 2022.
  • The 5-year median for Gains from Investment Securities is $1.1 million (2023), against an average of $1.7 million.
  • The largest annual shift saw Gains from Investment Securities tumbled 907.57% in 2021 before it surged 9991.72% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$2.5 million in 2021, then dropped by 12.5% to -$2.8 million in 2022, then skyrocketed by 98.77% to -$35000.0 in 2023, then rose by 8.57% to -$32000.0 in 2024, then skyrocketed by 2995.74% to $926636.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Gains from Investment Securities are $926636.0 (Q3 2025), $1.9 million (Q1 2025), and -$32000.0 (Q4 2024).